Xenon Pharmaceuticals reported highly positive Phase III X‑TOLE2 data for azetukalner, a Kv7 potassium channel opener, showing a substantial placebo‑adjusted reduction in monthly focal onset seizure frequency. The readout dramatically outperformed expectations and sent the company’s shares sharply higher, reviving commercial interest in the Kv7 target after past setbacks in the class. Investigators highlighted robust statistical significance and a large median effect size. The result repositions Kv7 as a credible mechanism for focal epilepsy and sets the stage for regulatory discussions and potential filing plans.